(Q38101884)

28 August 2017

title

Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives (English)

1 reference

28 August 2017

1 reference

Rashmi R Shah

1

1 reference

28 August 2017

Joel Morganroth

series ordinal

2

1 reference

28 August 2017

Devron R Shah

series ordinal

3

1 reference

28 August 2017

publication date

1 July 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

36

1 reference

28 August 2017

issue

7

1 reference

28 August 2017

page(s)

491-503

1 reference

Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Outcome and prognostic markers in severe drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Role of reactive metabolites in drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Current concepts of mechanisms in drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Drug-induced liver injury: insights from genetic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Pharmacogenetics of drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Mechanisms of drug-induced liver injury: from bedside to bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Role of immune reactions in drug-induced liver injury (DILI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Central role of mitochondria in drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Can pharmacogenetics help rescue drugs withdrawn from the market?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Risk factors for idiosyncratic drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Liver enzyme monitoring in patients treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Troglitazone-induced liver failure: a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Imatinib-induced toxic hepatitis: description of two cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Multiple myeloma emerging after prolonged gefitinib treatment for non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Mechanisms and outcomes of drug- and toxicant-induced liver toxicity in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Protein Tyrosine Phosphatase 1B (PTP1B) deficiency accelerates hepatic regeneration in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Signal transduction pathways involved in drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Phase II trial of sorafenib in advanced thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Sorafenib-induced liver failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Sorafenib-induced hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

The pathology of drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Interaction of innovative small molecule drugs used for cancer therapy with drug transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Kinetics and metabolism of paracetamol and phenacetin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

The 2006 Bernard B. Brodie Award Lecture. Cyp2e1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Treatment with gefitinib after erlotinib-induced liver injury: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Fatal hepatic necrosis following imatinib mesylate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Imatinib mesylate as a cause of acute liver failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Histological features of acute hepatitis after imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0048-4

The adaptive response (drug tolerance) helps to prevent drug-induced liver injury.

21 January 2018

1 reference

12 December 2020

Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity

1 reference

12 December 2020

Drug-induced hepatotoxicity: pharmacokinetic perspectives and strategies for risk reduction

1 reference

12 December 2020

Tyrosine kinases as targets for cancer therapy

1 reference

12 December 2020

Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations

1 reference

12 December 2020

Sorafenib-induced liver failure: a case report and review of the literature

1 reference

12 December 2020

Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury

1 reference

12 December 2020

Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms.

1 reference

12 December 2020

Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials

1 reference

12 December 2020

Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism

1 reference

12 December 2020

The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs

1 reference

12 December 2020

Erlotinib-induced acute hepatitis in a patient with pancreatic cancer.

1 reference

12 December 2020

Imatinib-induced fatal acute liver failure

1 reference

12 December 2020

Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population

1 reference

12 December 2020

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors

1 reference

12 December 2020

Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period

1 reference

12 December 2020

Histopathological study of the hepatic and renal toxicity associated with the co-administration of imatinib and acetaminophen in a preclinical mouse model.

1 reference

12 December 2020

Vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity

1 reference

12 December 2020

Ticrynafen-associated hepatic injury: analysis of 340 cases

1 reference

12 December 2020

Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs

1 reference

12 December 2020

Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration

1 reference

12 December 2020

Successful erlotinib treatment for a patient with gefitinib-related hepatotoxicity and lung adenocarcinoma refractory to intermittently administered gefitinib

1 reference

12 December 2020

10.1007/S40264-013-0048-4

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1028844573

0 references

1 reference